NEWS Calgent Biotechnology Co. Ltd. | Novel Drugs | Unmet Medical Needs NEWS Grand Opening of CALGENT’s Operations and R&D Headquarters Displays Comprehensive Drug Development Capabilities READ MORE → 【2026/3/25】Calgent’s “Operations and R&D Headquarters” Officially Inaugurated READ MORE → 【2026/1/1】Songzhi Administrative Office Relocates and Integrates Operations with R&D Laboratory READ MORE → 【2025/11/11】Phase I Clinical Trial for CAL056 (Fiberfate) Reached a New Milestone READ MORE → 【2023/5/4】Translation Research Center of Calgent Biotech was formally established READ MORE → 【2023/4/25】Phase I Clinical Trials for CAL056 Cancer Drug Completed in Taiwan and the U.S., Confirming Its Safety READ MORE → 【2021/5/19】Calgent Received MOEA “Biotech New Drug Company” Designation for CAL056’s R&D and Manufacturing READ MORE → 【2021/2/9】CAL056 received Taiwan FDA approval of Phase I READ MORE → 【2020/10/16】CAL056 received US FDA approval of Phase I READ MORE → 【2019/2/28】CAL056 received US FDA Orphan Drug Designation READ MORE →
Grand Opening of CALGENT’s Operations and R&D Headquarters Displays Comprehensive Drug Development Capabilities READ MORE →
【2026/1/1】Songzhi Administrative Office Relocates and Integrates Operations with R&D Laboratory READ MORE →
【2023/4/25】Phase I Clinical Trials for CAL056 Cancer Drug Completed in Taiwan and the U.S., Confirming Its Safety READ MORE →
【2021/5/19】Calgent Received MOEA “Biotech New Drug Company” Designation for CAL056’s R&D and Manufacturing READ MORE →
